VCM
ICPT

Vigilant Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Vigilant Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-117
Closed -$17K – 378
2016
Q2 		$17K Buy
+117
New +$17.1K ﹤0.01% 246

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vigilant Capital Management's ICPT Position: Q3 2016 in Review

Vigilant Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2016, closing a stake of 117 shares — an estimated $17K sold.

Vigilant Capital Management first reported a position in ICPT in Q2 2016 and held it in 1 quarter. The position peaked at $17K in Q2 2016. 172 funds tracked by Wall St. Rank hold ICPT as of Q3 2016.

  • Vigilant Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • Vigilant Capital Management sold 117 Intercept Pharmaceuticals, Inc. shares in Q3 2016, an estimated $17K.
  • Vigilant Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2016 and held it in 1 quarter.
  • Vigilant Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $17K in Q2 2016.
  • 172 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2016.

Based on Vigilant Capital Management's 13F filing for Q3 2016, filed 14 Oct 2016.